The following are comments by KEI, UACT, Social Security Works, HealthGap, Public Citizen, Dr. Ophira Ginsbug and James Love on an NIH proposed exclusive license for patents on a CAR T technology for “Treatment of FMS-Like Tyrosine Kinase 3 (FLT3)… Continue Reading →
Update. NIH sent us a 147 word response on November 23, 2018: NIH to KEI regarding Ovensa 23 NOV 2018. The brief reply states that “Prior to posting notices of a proposed grant of exclusive commercialization licenses, the NIH determines… Continue Reading →
On 9 November 2018, South Africa delivered the following statement on IP and competition policy at the WTO TRIPS Council under agenda item 13 on Intellectual Property and the Public Interest: Promoting Public Health Through Competition Law and Policy (an… Continue Reading →
On 9 November 2018, Brazil delivered the following statement on IP and competition policy at the WTO TRIPS Council under agenda item 13 on Intellectual Property and the Public Interest: Promoting Public Health Through Competition Law and Policy (an item… Continue Reading →
The United States-Mexico-Canada Agreement (USMCA) provisions on the term of protection of test data for new pharmaceutical products has received considerable attention, and in some cases, some inaccurate reports on the agreement have conflated the term for test data protection… Continue Reading →
KEI’s release of TPP Intellectual Property Chapter – May 11, 2015 Draft Link to full text of the IP Chapter: /tpp/11may2015-ip-text 2015:2 KEI TPP Briefing Note: The Evolution of the Article on Patents/Patentable Subject Matter in the Trans-Pacific Partnership Intellectual… Continue Reading →
The text of the proposed new U.S.-Canada-Mexico trade agreement is out, and available here from USTR. The agreement includes 34 chapters, 11 agreement annexes and 12 side letters. This is the first time the public has seen the text, even… Continue Reading →
Cases where a federal court in the United States determine there is infringement, but denies a permanent injunction. Revised, March 21, 2019 (All of the cases except for Cardiaq Valve Technologies involve patent infringement. The Cardiaq Value case involve trade… Continue Reading →
On August 20, 2018, KEI filed comments in response to the US Federal Trade Commission’s hearings and public comment process to address, “Competition and Consumer Protection in the 21st Century.” The goal of the process is to examine, “whether broad-based… Continue Reading →
On 12 June 2018 and 14 June 2018, the World Trade Organization (WTO) conducted a Trade Policy Review of Colombia. All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). The TPRM takes place… Continue Reading →